Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BHE202205

FXR Agonist

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: FXR Agonist
    Indications: NASH
    Research phase: Phase II
    Cooperation demands: License-out or co-development
  • Highlights

    1. This asset showed more potent activity than OCA during in vivo assays.


    2. More potent efficacy than GS9674 or OCA in different NASH animal models with lower doses.


    3. Wider safety window than OCA (67.6 fold VS 4.8 fold) and comparable lower estimated human dose(0.25 mg VS 25 mg).


    4. Efficacy has been showed in different animal NASH model.


    The asset showed more potent efficacy than GS9674 and OCA in different NASH animal models with lower doses.


    5. Development Timeline



  • Project Introduction

    1. Asset type: FXR Agonist

    2. Indication: NASH

    3. Modality: Small molecular

    4. Research phase: Phase I is finished in AU/Phase II is ongoing in CN

    5. Cooperation demands: License-out or co-development

    6. Research progress:

    (1) Phase I is finished in CN and AU.
    (2) Phase II is ongoing in CN.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message